No profile data available.
Acurx Pharmaceuticals, Inc. (ACXP) is a healthcare company in the antibacterial pharmaceuticals industry, based in Staten Island, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$7.97 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $7.06 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Acurx Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$7.06 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include China Pharma Holdings, Inc. (CPHI), Evaxion A/S (EVAX), Seres Therapeutics, Inc. (MCRB), BiomX Inc. (PHGE).